Dr. Armando Retana

D.D.S., M.D. | Oral and Maxillofacial Surgeon



  
  7322 E 91st St, Tulsa
  Oklahoma, 74133-6016

  918-392-0880    Maps & Directions
Dr. Armando Retana is a Tulsa, Oklahoma based Oral and Maxillofacial Surgeon who is specialized in Oral and Maxillofacial Surgery. He may accept the Medicare-approved amount. Patients may be billed for more than the Medicare deductible and coinsurance. His current practice location is 7322 E 91st St, Tulsa. Patients can reach him at 918-392-0880.
Dr. Armando Retana deals with the diagnosis, surgical and adjunctive treatment of diseases, injuries and defects involving both the functional and esthetic aspects of the hard and soft tissues of the oral and maxillofacial region.
Complete Profile:
Dr. Armando Retana speciality, credentials, practice address, contact phone number and fax are as below. Patients can directly walk in or can call on the below given phone number for appointment.
Name: Dr. Armando Retana
Specialization: Oral and Maxillofacial Surgeon
Gender:Male
Credentials: D.D.S., M.D.
Accepts Medicare Assignment:May Accept
Practice Address:7322 E 91st St, Tulsa,
Oklahoma, 74133-6016
Phone:918-392-0880
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS). NPI details are as mentioned below.
PAC ID: 3274754320
Enrollment ID: I20141015000809
NPI Number: 1023329901
NPI Enumeration Date: 25 Jun, 2010
NPI Last Update On: 08 Aug, 2016

Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address: 7322 E 91st St,
Tulsa, Oklahoma
Zip: 74133-6016
Patients can reach Dr. Armando Retana at 7322 E 91st St, Tulsa, Oklahoma or can call to book an appointment on 918-392-0880. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.

Comments/ Reviews: